Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery

Summary

It was the objective of this study to obtain best estimates of the prevalence of anti-PF4/heparin antibodies in patients not suspected to have clinical heparin-induced thrombocytopenia (HIT) prior to undergoing cardiac surgery and to determine whether preoperative antibody status and antibody class is predictive of postoperative thromboembolic outcomes, non-thromboembolic outcomes, length of stay, and mortality. PubMed and EMBASE online databases were searched up to July 2011, and we included studies involving adults undergoing cardiac surgery examining the relationship between preoperative anti-PF4/heparin antibodies (ELISA) and postoperative clinical outcomes. Five studies involving a combined total of 2,332 patients met our inclusion criteria. Preoperative anti-PF4/heparin antibodies were detected in 5–22% of patients. No study demonstrated an association between preoperative anti-PF4/heparin antibodies and postoperative thromboembolic outcomes or mortality. Three studies demonstrated a statistically significant association between preoperative anti-PF4/heparin antibodies and length of stay while two showed an association with non-thromboembolic complications. In the one study that examined outcomes by anti-PF4/heparin antibody class, IgM antibodies predicted non-thromboembolic complications and length-of-stay. None of the studies reported prior heparin exposure, and most studies did not examine the relationship of the absolute value of antibody titres (ELISA OD) and risk, nor the incidence of true/clinical HIT in preoperative positive or negative patients. In conclusion, pre-formed anti-PF4/heparin antibodies are common in patients undergoing cardiac surgery, but the available literature does not support that they predict postoperative thromboembolic complications or death. There does appear to be an association between anti-PF4/heparin antibodies and non-thromboembolic adverse events, but a causal relationship is unlikely.

Keywords

Heparin - anti-PF4/H - antibodies - cardiac surgery

• References

• 1 Visentin GP, Ford SE, Scott PJ. et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
• 2 Bauer TL, Arepally G, Konkle BA. et al. Prevalence of Heparin-Associated Antibodies without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. Circulation 1997; 95: 1242-1246.
• 3 Bennett-Guerrero E, Slaughter TF, White WD. et al. Preoperative anti-PF4/heparin level predicts adverse outcome after cardiac surgery. J Throac Cardiovasc Surg 2005; 130: 1567-1572.
• 4 Selleng S, Malowsky B, Itterman T. et al. Incidence and clinical relevance of antiplatelet factor 4/heparin antibodies before cardiac surgery. Am Heart J 2010; 160: 362-369.
• 5 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 6 Baroletti S, Piovella C, Fanikos J. et al. Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. Thromb Haemost 2008; 100: 1130-1135.
• 7 Greinacher A, Farner B, Kroll H. et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. Thromb Haemost 2005; 94: 132-135.
• 8 Visentin GP, Malik M, Cyganiak KA. et al. Patients treated with Unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 1996; 128: 376-383.
• 9 Kress DC, Solomon A, McDonald ML. et al. Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgery Outcomes. Ann Thorac Surg 2007; 83: 1737-1743.
• 10 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
• 11 Stribling K, Slaughter TF, Houle TT. et al. Beyond the platelet count: Heparin antibodies as independent risk predictors. Am Heart J 2007; 153: 900-906.
• 12 Paparella D, Scrascia G, Galeone A. et al. Formation of anti-platelet factor 4/heparin antibodies following cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J Thorac Cardiovasc Surg 2008; 136: 1456-1463.
• 13 Lubenow N, Hinz P, Thomaschewski S. et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115: 1797-1803.
• 14 Warkentin TE, Sheppard JI, Moore JC. et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005; 146: 341-346.
• 15 Pathophysiology and Diagnosis of Heparin-Induced Thrombocytopenia. American College of Chest Physicians 2010. Available at: http://www.chestnet.org/accp/article/chest-physician/pathophysiology-and-diagnosis-heparin-induced-thrombocytopenia Accessed August 23, 2011.
• 16 Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention.
• 17 The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Warkentin TE, Greinacher A. Chest 2004; 126: 3115-3375.
• 18 Ruf KM, Bensadoun ES, Davis GA. et al. A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb Haemost 2011; 105: 553-559.
• 19 Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100: 678-684.
• 20 Aquino RS, Pereira MS, Vairo BC. et al. Heparins from porcine and bovine intestinal mucosa: Are they similar drugs?. Thromb Haemost 2010; 103: 1005-1015.